Clinical TrialsThree Phase 3 inTandem trials have shown that sotagliflozin, combined with optimized insulin therapy, can reduce HbA1c levels, body fat, insulin doses, and episodes of severe hypoglycemia in type 1 diabetes patients.
LeadershipThe appointment of Mike Exton, Ph.D. as the new CEO, brings significant expertise in the cardiometabolic space, aligning well with Lexicon's focus areas and potentially benefiting the company's commercialization efforts and pipeline development.
Regulatory ApprovalLexicon's resubmitted NDA for Zynquista, targeting adults with type 1 diabetes and chronic kidney disease, has been acknowledged by the FDA, potentially alleviating investor concerns.